Mediport use as an acceptable standard for CAR T cell infusion

Mediport use as an acceptable standard for CAR T cell infusion

IntroductionMediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized. Concern for mediport dislodgement, cell infiltration, and ineffective therapy delivery to systemic circulatio...

Full description

Bibliographic Details
Main Authors: Maya Eylon, Snehit Prabhu, Samuel John, Maxwell J. M. King, Dhruv Bhatt, Kevin J. Curran, Courtney Erickson, Nicole A. Karras, Christine L. Phillips, Prakash Satwani, Michelle Hermiston, Erica Southworth, Susanne H. C. Baumeister, Julie-An Talano, Margaret L. MacMillan, Jenna Rossoff, Challice L. Bonifant, Gary Doug Myers, Rayne H. Rouce, Keri Toner, Timothy A. Driscoll, Emmanuel Katsanis, Dana B. Salzberg, Deborah Schiff, Satiro N. De Oliveira, Christian M. Capitini, Holly L. Pacenta, Thomas Pfeiffer, Niketa C. Shah, Van Huynh, Jodi L. Skiles, Ellen Fraint, Kevin O. McNerney, Troy C. Quigg, Joerg Krueger, John A. Ligon, Vanessa A. Fabrizio, Christina Baggott, Theodore W. Laetsch, Liora M. Schultz
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor T cell
immunotherapy
cancer
immune cell engineering
mediport
implanted catheter
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239132/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1239132/full

Similar Items